Antimicrobial peptides and peptidomimetics-potent therapeutic allies for staphylococcal infections

Current Pharmaceutical Design

Volumn 21, Issue 16, 2015, Pages 2073-2088

  Mohammad, Haroon ^a   Thangamani, Shankar ^a   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Antibacterial; Antibiotics; Antimicrobial peptides; Bacterial resistance; Immunomodulatory agents; MRSA; Multidrug resistance; Peptidomimetics; Staphylococci

Indexed keywords

ANTIBIOTIC AGENT; BRILACIDIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYTOKINE; DIVALENT ION; EPINECIDIN 1; FOWLICIDIN 1; HB 1345; INDOLICIDIN; INORGANIC SALT; ION; ISEGANAN; LYSOSTAPHIN; LYTIXAR; MU 1140; NISIN; NOVISPIRIN; NZ 2114; OMIGANAN; PARDAXIN; PEPTIDE 4; PEPTIDOMIMETIC AGENT; PEXIGANAN; PLECTASIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN 1; PROTEINASE; TEMPORIN A; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIMICROBIAL CATIONIC PEPTIDE; IMMUNOLOGIC FACTOR;

ADAPTATION; ANGIOGENESIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BIOLOGICAL ACTIVITY; CHEMOTAXIS; DIABETIC FOOT; DRUG BIOAVAILABILITY; HOST; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OINTMENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; WOUND HEALING; AMINO ACID SEQUENCE; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; STAPHYLOCOCCAL INFECTIONS;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR SEQUENCE DATA; PEPTIDOMIMETICS; STAPHYLOCOCCAL INFECTIONS;

EID: 84929452695     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150310102702     Document Type: Article

References (201)

1. Antimicrobial Resistance: Global Report on Surveillance 2014. France: World Health Organization, 2014.
2. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. 2013.
3. Aiello AE, D Lowy F, Wright LN, Larson EL. Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis 2006; 6(6): 335-41.
4. Cohen PR. Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection in participants of athletic activities. South Med J 2005; 98(6): 596-602.
5. Craven DE, Rixinger AI, Goularte TA, Mccabe WR. Methicillin-Resistant Staphylococcus-Aureus Bacteremia Linked to Intravenous Drug-Abusers Using a Shooting Gallery. Am J Med 1986; 80(5): 770-6.
6. Gilbert M, MacDonald J, Gregson D, et al. Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration. Can Med Assoc J 2006; 175(2): 149-54.
7. Herold BC, Immergluck LC, Maranan MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. Jama-J Am Med Assoc 1998; 279(8): 593-8.
8. Karamatsu ML, Thorp AW, Brown L. Changes in Community-Associated Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections Presenting to the Pediatric Emergency Department Comparing 2003 to 2008. Pediatr Emerg Care 2012; 28(2): 131-5.
9. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. New Engl J Med 2005; 352(5): 468-75.
10. Malcolm B. The rise of methicillin-resistant staphylococcus aureus in U.S. correctional populations. Journal of correctional health care : the official journal of the National Commission on Correctional Health Care 2011; 17(3): 254-65.
11. Regev-Yochay G, Rubinstein E, Barzilai A, et al. Methicillinresistant Staphylococcus aureus in neonatal intensive care unit. Emerging Infectious Diseases 2005; 11(3): 453-6.
12. Kassis C, Hachem R, Raad II, et al. Outbreak of communityacquired methicillin-resistant Staphylococcus aureus skin infections among health care workers in a cancer center. Am J Infect Control 2011; 39(2): 112-7.
13. Tristan A, Ferry T, Durand G, et al. Virulence determinants in community and hospital meticillin-resistant Staphylococcus aureus. J Hospital Infection 2007; 65 Suppl 2: 105-9.
14. Bocchini CE, Hulten KG, Mason EO, Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006; 117(2): 433-40.
15. David MZ, Daum RS. Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic. Clin Microbiol Rev 2010; 23(3): 616.
16. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359(9308): 753-9.
17. Odell CA. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections. Curr Opinion Pediatrics 2010; 22(3): 273-7.
18. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5: S368-77.
19. Chambers HF. Community-associated MRSA--resistance and virulence converge. N Eng J Med 2005; 352(14): 1485-7.
20. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Annals Emergency Med 2005; 45(3): 311-20.
21. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant staphylococcus aureus disease in three communities. New Engl J Med 2005; 352(14): 1436-44.
22. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007; 45(4): 1350-2.
23. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S-aureus infections among patients in the emergency department. New Engl J Med 2006; 355(7): 666-74.
24. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1(3): 147-55.
25. Locke JB, Morales G, Hilgers M, et al. Elevated Linezolid Resistance in Clinical cfr-Positive Staphylococcus aureus Isolates Is Associated with Co-Occurring Mutations in Ribosomal Protein L3. Antimicrobial Agents Chemotherapy 2010; 54(12): 5352-5.
26. Wilson P, Andrews JA, Charlesworth R, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemoth 2003; 51(1): 186-7.
27. Aldridge KE. Invitro Antistaphylococcal Activities of 2 Investigative Fluoroquinolones, Ci-960 and Win-57273, Compared with Those of Ciprofloxacin, Mupirocin (Pseudomonic Acid), and Peptide-Class Antimicrobial Agents. Antimicrobial Agents Chemotherapy 1992; 36(4): 851-3.
28. Chatterjee S, Chatterjee S, Lad SJ, et al. Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. J Antibiotics 1992; 45(6): 832-8.
29. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol 2013; 31(5): 379-82.
30. Tincu JA, Menzel LP, Azimov R, et al. Plicatamide, an antimicrobial octapeptide from Styela plicata hemocytes. J Biological Chem 2003; 278(15): 13546-53.
31. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19(3): 491-511.
32. Pinheiro da Silva F, Machado MC. Antimicrobial peptides: clinical relevance and therapeutic implications. Peptides 2012; 36(2): 308-14.
33. Lee IH, Cho Y, Lehrer RI. Effects of pH and salinity on the antimicrobial properties of clavanins. Infection Immunity 1997; 65(7): 2898-903.
34. Papagianni M. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 2003; 21(6): 465-99.
35. Boman HG, Agerberth B, Boman A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infection Immunity 1993; 61(7): 2978-84.
36. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Investigation 1989; 84(2): 553-61.
37. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochemical Biophys Res Communications 1998; 244(1): 253-7.
38. Schuerholz T, Brandenburg K, Marx G. Antimicrobial peptides and their potential application in inflammation and sepsis. Crit Care 2012; 16(2).
39. Aldridge KE. In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptideclass antimicrobial agents. Antimicrobial Agents Chemotherapy 1992; 36(4): 851-3.
40. Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res 2005; 30(7): 505-15.
41. Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24(12): 1551-7.
42. Sivertsen A, Isaksson J, Leiros HKS, Svenson J, Svendsen JS, Brandsdal BO. Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin. Bmc Struct Biol 2014; 14.
43. Falla TJ, Karunaratne DN, Hancock RE. Mode of action of the antimicrobial peptide indolicidin. J Biological Chem 1996; 271(32): 19298-303.
44. Ghiselli R, Giacometti A, Cirioni O, et al. Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/ tazobactam in experimental rat models of polymicrobial peritonitis. Critical Care Med 2008; 36(1): 240-5.
45. Robinson WE, Jr., McDougall B, Tran D, Selsted ME. Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils. J Leukocyte Biol 1998; 63(1): 94-100.
46. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. In vitro activity of omiganan pentahydrochloride tested against vancomycintolerant,-intermediate, and-resistant Staphylococcus aureus. Diagnostic Microbiol Infectious Disease 2008; 60(4): 399-403.
47. Anderegg TR, Fritsche TR, Jones RN, Quality Control Working G. Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide. J Clin Microbiol 2004; 42(3): 1386-7.
48. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrobial Agents Chemotherapy 2008; 52(3): 1187-9.
49. Melo MN, Castanho MA. Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation. Biochimica et Biophysica Acta 2007; 1768(5): 1277-90.
50. Rubinchik E, Dugourd D, Algara T, Pasetka C, Friedland HD. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrobial Agents 2009; 34(5): 457-61.
51. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J Leukocyte Biol 2005; 77(4): 451-9.
52. Noore J, Noore A, Li B. Cationic antimicrobial peptide LL-37 is effective against both extra-and intracellular Staphylococcus aureus. Antimicrobial Agents Chemotherapy 2013; 57(3): 1283-90.
53. Fukumoto K, Nagaoka I, Yamataka A, et al. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatric surgery Int 2005; 21(1): 20-4.
54. Jacobsen F, Mohammadi-Tabrisi A, Hirsch T, et al. Antimicrobial activity of the recombinant designer host defence peptide Pnovispirin G10 in infected full-thickness wounds of porcine skin. J Antimicrobial Chemotherapy 2007; 59(3): 493-8.
55. Sawai MV, Waring AJ, Kearney WR, et al. Impact of singleresidue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides. Protein Engineering 2002; 15(3): 225-32.
56. Simonetti O, Cirioni O, Goteri G, et al. Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. Peptides 2008; 29(4): 520-8.
57. Wade D, Silberring J, Soliymani R, et al. Antibacterial activities of temporin A analogs. FEBS letters 2000; 479(1-2): 6-9.
58. Mosca DA, Hurst MA, So W, Viajar BS, Fujii CA, Falla TJ. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrobial Agents Chemotherapy 2000; 44(7): 1803-8.
59. Cirioni O, Silvestri C, Pierpaoli E, et al. IB-367 pre-treatment improves the in vivo efficacy of teicoplanin and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus. J Med Microbiol 2013; 62(Pt 10): 1552-8.
60. Giacometti A, Cirioni O, Ghiselli R, et al. Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. Gut 2003; 52(6): 874-8.
61. Fitzgerald-Hughes D, Devocelle M, Humphreys H. Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives. FEMS Immunol Med Microbiol 2012; 65(3): 399-412.
62. Kumar K, Chopra S. New drugs for methicillin-resistant Staphylococcus aureus: an update. J Antimicrobial Chemotherapy 2013; 68(7): 1465-70.
63. Steinberg DA, Hurst MA, Fujii CA, et al. Protegrin-1: a broadspectrum, rapidly microbicidal peptide with in vivo activity. Antimicrobial Agents Chemotherapy 1997; 41(8): 1738-42.
64. Tran D, Tran P, Roberts K, et al. Microbicidal properties and cytocidal selectivity of rhesus macaque theta defensins. Antimicrobial Agents Chemotherapy 2008; 52(3): 944-53.
65. Lamb HM, Wiseman LR. Pexiganan acetate. Drugs 1998; 56(6): 1047-52; discussion 53-4.
66. Gottler LM, Ramamoorthy A. Structure, membrane orientation, mechanism, and function of pexiganan--a highly potent antimicrobial peptide designed from magainin. Biochimica et biophysica acta 2009; 1788(8): 1680-6.
67. Mygind PH, Fischer RL, Schnorr KM, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005; 437(7061): 975-80.
68. Xiong YQ, Hady WA, Deslandes A, et al. Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrobial Agents Chemotherapy 2011; 55(11): 5325-30.
69. Brinch KS, Tulkens PM, Van Bambeke F, Frimodt-Moller N, Hoiby N, Kristensen HH. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. J Antimicrobial Chemotherapy 2010; 65(8): 1720-4.
70. Bommineni YR, Achanta M, Alexander J, Sunkara LT, Ritchey JW, Zhang G. A fowlicidin-1 analog protects mice from lethal infections induced by methicillin-resistant Staphylococcus aureus. Peptides 2010; 31(7): 1225-30.
71. Faber C, Stallmann HP, Lyaruu DM, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrobial Agents Chemotherapy 2005; 49(6): 2438-44.
72. Stallmann HP, Faber C, Bronckers AL, Nieuw Amerongen AV, Wuisman PI. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11-or gentamicin-containing calcium phosphate cement. J Antimicrobial Chemotherapy 2004; 54(2): 472-6.
73. Nibbering PH, Ravensbergen E, Welling MM, et al. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infection Immunity 2001; 69(3): 1469-76.
74. Brouwer CP, Welling MM. Various routes of administration of (99m)Tc-labeled synthetic lactoferrin antimicrobial peptide hLF 1-11 enables monitoring and effective killing of multidrug-resistant Staphylococcus aureus infections in mice. Peptides 2008; 29(7): 1109-17.
75. Brouwer CP, Rahman M, Welling MM. Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 2011; 32(9): 1953-63.
76. Saravolatz LD, Pawlak J, Johnson L, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillinresistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrobial Agents Chemotherapy 2012; 56(8): 4478-82.
77. Isaksson J, Brandsdal BO, Engqvist M, Flaten GE, Svendsen JS, Stensen W. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem 2011; 54(16): 5786-95.
78. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiotics 2013; 66(10): 571-91.
79. Mohamed MF, Hamed MI, Panitch A, Seleem MN. Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides. Antimicrobial Agents Chemotherapy 2014; 58(7): 4113-22.
80. Heunis TD, Smith C, Dicks LM. Evaluation of a nisin-eluting nanofiber scaffold to treat Staphylococcus aureus-induced skin infections in mice. Antimicrobial Agents Chemotherapy 2013; 57(8): 3928-35.
81. Brumfitt W, Salton MR, Hamilton-Miller JM. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrobial Chemotherapy 2002; 50(5): 731-4.
82. Vaucher RA, da Motta Ade S, Brandelli A. Evaluation of the in vitro cytotoxicity of the antimicrobial peptide P34. Cell Biol Int 2010; 34(3): 317-23.
83. Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrobial Agents 2009; 33(1): 70-4.
84. Ghobrial O, Derendorf H, Hillman JD. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci 2010; 99(5): 2521-8.
85. Pan CY, Chen JY, Cheng YS, et al. Gene expression and localization of the epinecidin-1 antimicrobial peptide in the grouper (Epinephelus coioides), and its role in protecting fish against pathogenic infection. DNA Cell Biol 2007; 26(6): 403-13.
86. Huang HN, Rajanbabu V, Pan CY, Chan YL, Wu CJ, Chen JY. Use of the antimicrobial peptide Epinecidin-1 to protect against MRSA infection in mice with skin injuries. Biomaterials 2013; 34(38): 10319-27.
87. Lin WJ, Chien YL, Pan CY, et al. Epinecidin-1, an antimicrobial peptide from fish (Epinephelus coioides) which has an antitumor effect like lytic peptides in human fibrosarcoma cells. Peptides 2009; 30(2): 283-90.
88. Fernandez-Lopez S, Kim HS, Choi EC, et al. Antibacterial agents based on the cyclic D, L-alpha-peptide architecture. Nature 2001; 412(6845): 452-5.
89. Huang HN, Pan CY, Chan YL, Chen JY, Wu CJ. Use of the antimicrobial peptide pardaxin (GE33) to protect against methicillinresistant Staphylococcus aureus infection in mice with skin injuries. Antimicrobial Agents Chemotherapy 2014; 58(3): 1538-45.
90. Oren Z, Shai Y. A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus. Eur J Biochem/ FEBS 1996; 237(1): 303-10.
91. Huang TC, Chen JY. Proteomic analysis reveals that pardaxin triggers apoptotic signaling pathways in human cervical carcinoma HeLa cells: cross talk among the UPR, c-Jun and ROS. Carcinogenesis 2013; 34(8): 1833-42.
92. Menousek J, Mishra B, Hanke ML, Heim CE, Kielian T, Wang G. Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300. Int J Antimicrobial Agents 2012; 39(5): 402-6.
93. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biological Chem 2001; 276(8): 5707-13.
94. Zhu C, Tan H, Cheng T, et al. Human beta-defensin 3 inhibits antibiotic-resistant Staphylococcus biofilm formation. J Surgical Res 2013; 183(1): 204-13.
95. Midorikawa K, Ouhara K, Komatsuzawa H, et al. Staphylococcus aureus susceptibility to innate antimicrobial peptides, betadefensins and CAP18, expressed by human keratinocytes. Infection Immunity 2003; 71(7): 3730-9.
96. Li Q, Zhou Y, Dong K, Guo X. Potential therapeutic efficacy of a bactericidal-immunomodulatory fusion peptide against methicillinresistant Staphylococcus aureus skin infection. App Microbiol Biotechnol 2010; 86(1): 305-9.
97. Jung S, Mysliwy J, Spudy B, et al. Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules. Antimicrobial Agents Chemotherapy 2011; 55(3): 954-60.
98. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrobial Agents Chemotherapy 2003; 47(5): 1589-97.
99. Desbois AP, Gemmell CG, Coote PJ. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrobial Agents 2010; 35(6): 559-65.
100. Kumar JK. Lysostaphin: an antistaphylococcal agent. App Microbiol Biotechnol 2008; 80(4): 555-61.
101. Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chemical Biol 2009; 4(1): 65-74.
102. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3(3): 238-50.
103. Wu M, Maier E, Benz R, Hancock RE. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 1999; 38(22): 7235-42.
104. Wu M, Hancock RE. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J Biological Chem 1999; 274(1): 29-35.
105. Matsuzaki K, Murase O, Fujii N, Miyajima K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 1996; 35(35): 11361-8.
106. Hasper HE, Kramer NE, Smith JL, et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 2006; 313(5793): 1636-7.
107. Schneider T, Kruse T, Wimmer R, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 2010; 328(5982): 1168-72.
108. Zhang L, Parente J, Harris SM, Woods DE, Hancock RE, Falla TJ. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrobial Agents Chemotherapy 2005; 49(7): 2921-7.
109. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrobial Agents Chemotherapy 2002; 46(3): 605-14.
110. Xiong YQ, Yeaman MR, Bayer AS. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrobial Agents Chemotherapy 1999; 43(5): 1111-7.
111. Subbalakshmi C, Sitaram N. Mechanism of antimicrobial action of indolicidin. FEMS microbiology letters 1998; 160(1): 91-6.
112. Nan YH, Park KH, Park Y, et al. Investigating the effects of positive charge and hydrophobicity on the cell selectivity, mechanism of action and anti-inflammatory activity of a Trp-rich antimicrobial peptide indolicidin. FEMS Microbiol letters 2009; 292(1): 134-40.
113. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414(6862): 454-7.
114. Scott MG, Dullaghan E, Mookherjee N, et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 2007; 25(4): 465-72.
115. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in sepsis. Scandinavian J Infectious Diseases 2003; 35(9): 535-44.
116. Zisman DA, Kunkel SL, Strieter RM, et al. MCP-1 protects mice in lethal endotoxemia. J Clin Investigation 1997; 99(12): 2832-6.
117. van der Does AM, Hensbergen PJ, Bogaards SJ, et al. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J Immunol 2012; 188(10): 5012-9.
118. van der Does AM, Bogaards SJ, Ravensbergen B, Beekhuizen H, van Dissel JT, Nibbering PH. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrobial Agents Chemotherapy 2010; 54(2): 811-6.
119. Yang D, Chertov O, Oppenheim JJ. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J Leukoc Biol 2001; 69(5): 691-7.
120. Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002; 106(1): 20-6.
121. Tjabringa GS, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol 2006; 140(2): 103-12.
122. Mookherjee N, Brown KL, Bowdish DM, et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006; 176(4): 2455-64.
123. Montreekachon P, Chotjumlong P, Bolscher JG, Nazmi K, Reutrakul V, Krisanaprakornkit S. Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts. J Periodontal Res 2011; 46(3): 327-37.
124. Mookherjee N, Lippert DN, Hamill P, et al. Intracellular receptor for human host defense peptide LL-37 in monocytes. J Immunol 2009; 183(4): 2688-96.
125. Tjabringa GS, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Imm 2006; 140(2): 103-12.
126. Niyonsaba F, Ushio H, Nakano N, et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Investigative Dermatol 2007; 127(3): 594-604.
127. Ramos R, Silva JP, Rodrigues AC, et al. Wound healing activity of the human antimicrobial peptide LL37. Peptides 2011; 32(7): 1469-76.
128. Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin antimicrobial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Investigative Dermatol 2003; 120(3): 379-89.
129. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Investigation 2003; 111(11): 1665-72.
130. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabetic medicine : a journal of the British Diabetic Association 2003; 20(2): 159-61.
131. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrobial Chemotherapy 2005; 55(2): 240-5.
132. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabetic medicine : a journal of the British Diabetic Association 1999; 16(9): 767-71.
133. Fejfarova V, Jirkovska A, Skibova J, Petkov V. [Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome]. Vnitrni lekarstvi 2002; 48(4): 302-6.
134. Lipsky BA, Berendt AR, Cornia PB, et al2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012; 54(12): e132-73.
135. Galkowska H, Podbielska A, Olszewski WL, et al. Epidemiology and prevalence of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis in patients with diabetic foot ulcers: focus on the differences between species isolated from individuals with ischemic vs. neuropathic foot ulcers. Diabetes Res Clin Practice 2009; 84(2): 187-93.
136. Rosenberg CS. Wound healing in the patient with diabetes mellitus. Nursing Clin North Am 1990; 25(1): 247-61.
137. Hirsch T, Spielmann M, Zuhaili B, et al. Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J Gene Med 2009; 11(3): 220-8.
138. Zhang L, Scott MG, Yan H, Mayer LD, Hancock RE. Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. Biochemistry 2000; 39(47): 14504-14.
139. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biological Chem 1996; 271(45): 28375-81.
140. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrobial Agents Chemotherapy 1999; 43(4): 782-8.
141. Ge Y, MacDonald D, Henry MM, et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 1999; 35(1): 45-53.
142. Barker KF. Antibiotic resistance: a current perspective. Br J Clin Pharmacol 1999; 48(2): 109-24.
143. Nordmann P, Guibert M. Extended-spectrum beta-lactamases in Pseudomonas aeruginosa. J Antimicrobial Chemotherapy 1998; 42(2): 128-31.
144. Cohen J, McConnell JS. Antibiotic-induced endotoxin release. Lancet 1985; 2(8463): 1069-70.
145. Shenep JL, Barton RP, Mogan KA. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1985; 151(6): 1012-8.
146. Mannis MJ. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis. Transactions Am Ophthalmological Soc 2002; 100: 243-71.
147. Fraser J, West M, Krieger T, Taylor R, Erfle D. Compositions and methods for treating infections using analogues of indolicidin. Google Patents; 2004.
148. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005; 353(1): 38-52.
149. Herve F, Urien S, Albengres E, Duche JC, Tillement JP. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinetics 1994; 26(1): 44-58.
150. Rothstein DM, Spacciapoli P, Tran LT, et al. Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrobial Agents Chemotherapy 2001; 45(5): 1367-73.
151. Bowdish DME, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock REW. Impact of LL-37 on anti-infective immunity. J Leukocyte Biol 2005; 77(4): 451-9.
152. Chu HL, Yu HY, Yip BS, et al. Boosting Salt Resistance of Short Antimicrobial Peptides. Antimicrobial Agents Chemotherapy 2013; 57(8): 4050-2.
153. Verhoef JC, Bodde HE, Deboer AG, et al. Transport of Peptide and Protein Drugs across Biological-Membranes. Eur J Drug Metab Ph 1990; 15(2): 83-93.
154. Houston ME, Kondejewski LH, Karunaratne DN, et al. Influence of preformed alpha-helix and alpha-helix induction on the activity of cationic antimicrobial peptides. J Pept Res 1998; 52(2): 81-8.
155. Osapay K, Tran D, Ladokhin AS, White SH, Henschen AH, Selsted ME. Formation and characterization of a single Trp-Trp cross-link in indolicidin that confers protease stability without altering antimicrobial activity. J Biological Chemistry 2000; 275(16): 12017-22.
156. R TB, Jeffrey A, Siahaan TJ, Gangwar S, Pauletti GM. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Delivery Rev 1997; 27(2-3): 235-56.
157. Rozek A, Powers JP, Friedrich CL, Hancock RE. Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 2003; 42(48): 14130-8.
158. Giuliani A, Rinaldi AC. Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches. Cell Mol Life Sci 2011; 68(13): 2255-66.
159. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004; 172(2): 1169-76.
160. Sieprawska-Lupa M, Mydel P, Krawczyk K, et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureusderived proteinases. Antimicrobial Agents Chemotherapy 2004; 48(12): 4673-9.
161. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 2006; 8(1): 11-26.
162. Peschel A. How do bacteria resist human antimicrobial peptides? Trends Microbiol 2002; 10(4): 179-86.
163. Kupferwasser LI, Skurray RA, Brown MH, Firth N, Yeaman MR, Bayer AS. Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: role of the qacA locus. Antimicrobial Agents Chemotherapy 1999; 43(10): 2395-9.
164. Schmidtchen A, Pasupuleti M, Morgelin M, et al. Boosting Antimicrobial Peptides by Hydrophobic Oligopeptide End Tags. J Biological Chem 2009; 284(26): 17584-94.
165. Garzoni C, Francois P, Huyghe A, et al. A global view of Staphylococcus aureus whole genome expression upon internalization in human epithelial cells. Bmc Genomics 2007; 8.
166. Ong ZY, Cheng J, Huang Y, et al. Effect of stereochemistry, chain length and sequence pattern on antimicrobial properties of short synthetic beta-sheet forming peptide amphiphiles. Biomaterials 2014; 35(4): 1315-25.
167. Chatterjee S, Chatterjee DK, Jani RH, et al. Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J Antibiotics 1992; 45(6): 839-45.
168. PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic [press release]. April 23, 2012.
169. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 47(12): 1537-45.
170. Markova A, Mostow EN. US skin disease assessment: ulcer and wound care. Dermatologic clinics 2012; 30(1): 107-11, 9.
171. Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 2013; 57(10): 4605-7.
172. Kollef M, Pittet D, Sanchez Garcia M, et al. A randomized doubleblind trial of iseganan in prevention of ventilator-associated pneumonia. Am J Respiratory Critical Care Med 2006; 173(1): 91-7.
173. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheterassociated infections. J Antimicrobial Chemotherapy 2008; 61(5): 1092-8.
174. Mensa B, Howell GL, Scott R, DeGrado WF. Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16. Antimicrobial Agents Chemotherapy 2014; 58(9): 5136-45.
175. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Eng J Med 2006; 355(7): 666-74.
176. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA : the J Am Med Assoc 2012; 308(1): 50-9.
177. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children (vol 52, pg e18, 2011). Clin Infect Dis 2011; 53(3): 319.
178. Stevens DL, Bisno AL, Chambers HF, et al. Executive summary: practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of america. Clin Infect Dis 2014; 59(2): 147-59.
179. Mulvey MR, MacDougall L, Cholin B, et al. Communityassociated methicillin-resistant Staphylococcus aureus, Canada. Emerging Infectious Diseases 2005; 11(6): 844-50.
180. Simor AE, Stuart TL, Louie L, et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrobial Agents Chemotherapy 2007; 51(11): 3880-6.
181. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus Systemic Antimicrobial Therapy for Treating Mildly Infected Diabetic Foot Ulcers: A Randomized, Controlled, Double-Blinded, Multicenter Trial of Pexiganan Cream. Clin Infect Dis 2008; 47(12): 1537-45.
182. Schwab U, Gilligan P, Jaynes J, Henke D. In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens. Antimicrobial Agents Chemotherapy 1999; 43(6): 1435-40.
183. Chalekson CP, Neumeister MW, Jaynes J. Treatment of infected wounds with the antimicrobial peptide D2A21. J Trauma 2003; 54(4): 770-4.
184. Chalekson CP, Neumeister MW, Jaynes J. Improvement in burn wound infection and survival with antimicrobial peptide D2A21 (Demegel). Plastic Reconstructive Surgery 2002; 109(4): 1338-43.
185. Crunkhorn S. Antibacterial drugs: New antibiotics on the horizon? Nat Rev Drug Discovery 2013; 12(2): 99.
186. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39(6): 776-82.
187. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006; 155(4): 680-7.
188. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36(3): 281-5.
189. Carbon C. Costs of treating infections caused by methicillinresistant staphylococci and vancomycin-resistant enterococci. J Antimicrobial Chemotherapy 1999; 44 Suppl A: 31-6.
190. McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the Decolonization of Methicillin-Resistant Staphylococcus aureus. Pharmacotherapy 2009; 29(3): 263-80.
191. McDougal LK, Fosheim GE, Nicholson A, et al. Emergence of Resistance among USA300 Methicillin-Resistant Staphylococcus aureus Isolates Causing Invasive Disease in the United States. Antimicrobial Agents Chemotherapy 2010; 54(9): 3804-11.
192. Tegos G, Mylonakis E. Antimicrobial Drug Discovery: Emerging Strategies.2012.
193. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 49(7): 1072-9.
194. Mohamed MF, Seleem MN. Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillinresistant Staphylococcus aureus (MRSA) skin infection. Drug design, Development Therapy 2014; 8: 1979-83.
195. Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96(9): 3086-93.
196. Ganz T, Selsted ME, Szklarek D, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Investigation 1985; 76(4): 1427-35.
197. Eisenhauer PB, Harwig SS, Szklarek D, Ganz T, Selsted ME, Lehrer RI. Purification and antimicrobial properties of three defensins from rat neutrophils. Infection Immunity 1989; 57(7): 2021-7.
198. Lee PH, Rudisill JA, Lin KH, et al. HB-107, a nonbacteriostatic fragment of the antimicrobial peptide cecropin B, accelerates murine wound repair. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2004; 12(3): 351-8.
199. Steinstraesser L, Hirsch T, Schulte M, et al. Innate defense regulator peptide 1018 in wound healing and wound infection. PloS one 2012; 7(8): e39373.
200. Wieczorek M, Jenssen H, Kindrachuk J, et al. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol 2010; 17(9): 970-80.
201. Bacha JD, Oreola Lee, Ken Scott, Monisha. The Innate Defense. Modern Drug Discov 2004; 7(2): 43-6.